Background: We previously demonstrated increased hip bone mineral density (BMD) and worsening in insulin resistance after 48 weeks of rosuvastatin in HIV-infected adults on antiretroviral therapy (ART). Here, we present the final 96 week results.
Methods: The Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN-HIV) trial is a randomized, double-blind, placebo-controlled trial to evaluate the effect of rosuvastatin on markers of cardiovascular risk and skeletal health in HIV over 96 weeks. Subjects were on stable ART with HIV-1 RNA <1000 copies/mL, LDL-cholesterol <130 mg/dL, and immune activation (CD8+CD38+HLA-DR+ >19% and/or hsCRP >2 mg/L). Subjects were randomized 1:1 to daily rosuvastatin 10 mg or matching placebo, and stratified by protease inhibitor use and presence/absence of osteopenia. Bone primary endpoint was DXA-measured changes in total hip BMD; secondary endpoint was change in homeostatic model assessment of insulin resistance (HOMA-IR), calculated as fasting [insulin (uIU/mL)*glucose (mg/dL)]/450. Primary analyses were intent-to-treat. Statistical tests included multivariable linear regression.
Results: 147 subjects enrolled;78% male, 70% black; median age 47 years and CD4 count 613 cells/µL; 78% had HIV-1 RNA<50 copies/mL. At baseline, study arms were well balanced; 23% were osteopenic at the hip and 22% at the spine. No participants had diabetes, but 18% in statin and 15% in placebo had fasting glucose >100 mg/dL. At week 96, no significant differences in hip BMD (p=0.52) or spine BMD (p=0.96) were seen between study arms. Although changes in fasting glucose by week 96 were not significantly different between the rosuvastatin and placebo (p=0.14), 20 (32%) in the rosuvastatin and 12 (5%) in the placebo arm had glucose >100 mg/dL and 1 (2%) in the rosuvastatin and 2 (3%) in the placebo arm had fasting glucose >125 mg/dL. The rosuvastatin arm had significantly greater 96 week increases in insulin (mean 49.8 [SE 86.4]% versus 20.2 [138.4]%; p=0.009) and in HOMA-IR (72.6 [109.9]% vs. 33.0 [158.3]%; p=0.009). In multivariate models, 96 week changes in HOMA-IR were associated with statin use but not age, race, family history of diabetes, hepatitis C, or change in body composition.
Conclusions: Despite an initial beneficial effect of rosuvastatin on hip BMD, no longer term benefit was observed. The detrimental impact on insulin resistance persisted. Further data is needed to determine the risk/benefit of statins in HIV-infected persons.